1. Ensuring the supply of medicines to the patients that need them,
2. Supporting governments and health systems on the ground,
3. The search for vaccines, diagnostics and treatments to help in the fight against the coronavirus.
We are committed to working collaboratively across the research and healthcare communities, utilising our world-leading science, people and resources to tackle this outbreak. We are doing this by:
Boehringer Ingelheim immediately identified the areas of expertise, where we can best contribute to developing therapies for COVID-19 in close collaboration with academic researchers, international institutions and others in the pharma industry. Boehringer Ingelheim has joined a fast track call for project submissions to develop therapies and diagnostic tools initiated by the Innovative Medicines Initiative (IMI) of the European Union to accelerate the development of potential therapies for COVID-19. Boehringer Ingelheim is working to develop neutralizing antibodies against the SARS-CoV-2 spike protein. In addition, we are investigating our existing pipeline and in-market compounds as well as compounds from former HIV and HCV research activities. Furthermore, Boehringer Ingelheim is conducting a computational screening of its entire molecule library of more than one million compounds with the aim of identifying novel small molecules with activity against the virus. Learn more about Boehringer Ingelheim’s engagement in the fight against COVID-19.
Chiesi has announced today a new €3 million fund to support efforts to address this crisis in Italy. This fund will support a range of actions including donations of personal protective equipment, ventilators and sanitising gel in response to requests from hospitals and other health institutions. The company has also made direct donations of drugs for respiratory diseases to hospitals in China and Italy. Chiesi has also set up a process where team members in Italy can donate "virtual" hours of work to an association of volunteers in Parma to support emergency response. The company converted the donated hours worked into a monetary donation, which was then doubled by the Chiesi Group. In two weeks close to € 70.000 have already been collected.
GSK is expanding vaccines collaborations, working with five partner companies and research groups across the world, including in the USA and China. This builds on its previous announcements to make its vaccine adjuvant technology available to support COVID-19 vaccine research programmes. The use of an adjuvant is of particular importance in a pandemic situation since it may reduce the amount of vaccine doses to be produced, and therefore contributing to the protection of more people.
GSK is entering a new collaborative research effort, the COVID-19 Therapeutics Accelerator, by making available compounds from its libraries for screening, with the aim of bringing forward the most promising molecules that could be used to treat cases of COVID-19.
GSK is also evaluating its marketed medicines and those in development, to determine if any could be used beyond their current indications, and evaluating options to make available our specialised laboratory space to help in research and testing of COVID-19.
GSK is also donating surplus reagents to countries to support diagnostic testing, preparing to do the same for surplus personal protective equipment (PPE) and have initiated new volunteering processes for employees, to enable those with medical or specialist expertise to provide support to frontline health workers and national governments.
GSK Consumer Healthcare is prioritising actions in its supply chain to deliver more consumer products that are in high demand, due to COVID-19. This includes increasing production for pain relief brands and multi-vitamins and dietary supplements.
With the global health crisis unfolding, it is very important to help the personnel who are sacrificing themselves for the benefit of the whole country and to ensure safe working conditions for them, according to Agnė Gaižauskienė, CEO of IFPA - the Lithuanian Innovative Pharmaceutical Industry Association.
“Lithuanian hospitals lack personal protection equipment: respirators, disposable coveralls and other items. Now more than ever, we need a concerted effort and close collaboration to achieve the common goal, so we have joined other business organisations and contributed support directed specifically at procuring personal protection equipment for healthcare professionals. We are currently working hard to secure speedy delivery of the equipment so that the personnel dealing directly with the COVID-19 virus receive the much needed protection as soon as possible,” Ms Gaižauskienė said.
IFPA, together with other local partners, has raised nearly EUR 360,000 for the purchase of personal protection equipment. Ms Gaižauskienė added that the Innovative Pharmaceutical Industry Association continues to look for more opportunities to help healthcare professionals and workers.
“We have also initiated an additional IFPA member support fund within the association, which will be used to help medical staff. We will continue to do our utmost to take care of those who are rescuing lives every day and are currently in the forefront of the fight against COVID-19,” Ms Gaižauskienė said.
iF! Gx colleagues joined the initiative very fast, and as of 23 March there are 187 volunteers covering the call center with no risk attached, as everyone is connected via their mobile phones and they work from home, covering shifts from 7 a.m. to 10 p.m. every day.
iF! volunteers are answering hundreds of phone calls about corona symptoms, but also about contagion prevention, travel restrictions and even gas delivery! The citizens feedback is brilliant, and the feeling the volunteers got in return is priceless.
For more information on this initiative, read here.
- Ipsen Global donated €2 million to the Institut Pasteur to support the 21 research projects currently ongoing to combat COVID-19.
- Ipsen Benelux donated 700 medical masks to various hospitals in Gent for healthcare workers on the front lines.
- Ipsen France is supporting France Biotech, MedTech and France Digital in a public-private initiative, “Health Innovation Coalition - Health Crisis” to alleviate congestion in the healthcare system and ensure patients with diseases unrelated to COVID-19 experience no disruption in treatment. Regional initiatives in France also include donations of 500 gowns to local hospitals, while ensuring patients are still able to receive the medicines they need, donation of medical masks and medical gloves to local healthcare workers.
- Ipsen Greece donated two ventilators for intensive care units following a call from local health authorities who were anticipating a shortage in medical equipment.
- Ipsen Iberia is working on a program where all coupon restaurants of the teams for March and April will be donated to the Red Cross.
- Ipsen Italy allocated its entire 2020 Grants and Donations budget (100,000€) to the Bergamo Hospital in northern Italy, one of the regions hit hardest by COVID-19, for the purchase of ventilators and non-invasive ventilating materials. Furthermore, 100,000€ will be donated to the Italian Civil Protection, which coordinates health efforts throughout the country, plus a newly created delivery service of oral oncological drugs for patients with kidney cancer.
Thanks to J&J diversification, size and scale, it has been able to take rapid action across its Pharmaceutical, Consumer and Medical Devices businesses, as well as their Supply Chain and other supporting functions, to help stay ahead of the pandemic. Beyond seeking an optimal vaccine candidate, to date J&J efforts have included: Making available currently marketed antivirals to test their potential efficacy; Collaborating with industry partners to screen a library of antiviral molecules, with the aim to identify potential treatments; Working with regulators, healthcare organisations, institutions and communities worldwide to maximise their research platforms; Supporting healthcare professionals through making available tools, such as personal equipment (for instance via a RMB 1 million donation to the China Red Cross Foundation), a surgical generator and other devices for the newly-built isolation hospitals, protective suits, and a million masks among others; Last but not least, working with Governments to bring support on the ground, such as the ongoing cooperation with Belgium to use Janssen own laboratories in Beerse to significantly increase the capacity for COVID-19 testing. Cooperation also includes the new production of disinfectant hand liquid in Janssen Manufacturing Plant in Geel (Belgium).
The Menarini Group is also providing financial support as well as in-kind donations to organisations in the front line across Europe and beyond, commented Dr Eric Cornut, Chairman of Menarini Group.
For 170 years, our scientists and experts at Pfizer have addressed global health challenges. As part of our immediate response, we identified anti-viral compounds in our libraries which may have potential to address COVID-19. We are engaging with a third party to screen these compounds under an accelerated timeline and currently expect to have the results back by the end of March. We are also working with our partner BioNTech to co-develop a potential COVID-19 vaccine.
On a broader scale, Pfizer is committed to working as one team across the industry to harness our scientific expertise, technical skills and manufacturing capabilities to combat this evolving crisis. We have made five promises that will help scientists more rapidly bring forward therapies and vaccines to protect humankind from this escalating pandemic and prepare the industry to better respond to future global health crises.
Our Relief Efforts
Pfizer is grateful to the medical professionals on the front lines of this pandemic. We have an extensive global network of medical practitioners and experts, many of whom feel called to support their communities in the diagnosis, treatment and provision of public health support during this time. We respect their courage and selflessness to serve and have established a medical service policy that will allow these colleagues up to 13 weeks of paid leave, or longer if necessary, to provide this support.
Pfizer and the Pfizer Foundation have a long history of addressing humanitarian disasters. We are working with governments and international NGOs to respond to the COVID-19 pandemic by donating much needed medications and vaccines and working to support front line health workers.
In Italy, Pfizer’s affiliate is making available, free of charge, €2.5 million worth of medicines and vaccines that can be used in prevention and management of serious consequences related to COVID-19 in impacted regions. Pfizer is also dedicating resources to ensure safe and timely home delivery of essential drugs for patients with life threatening and rare diseases, such as haemophilia.
In view of the rapidly changing and ever-challenging COVID-19 pandemic situation, Sanofi is leveraging its expertise and experience in a number of ways to address this public health crisis.
In collaboration with the Biomedical Advanced Research and Development Authority (BARDA), Sanofi is taking previous work on a SARS vaccine candidate to advance a novel vaccine for COVID-19 using its recombinant DNA technology. The company is also collaborating with Translate Bio to develop a novel mRNA vaccine.
Sanofi is investigating whether its existing medicines may be effective in treating COVID-19. The first non-U.S. patient has been treated as part of a global clinical program evaluating whether Sanofi and Regeneron’s rheumatoid arthritis drug may ameliorate the life-threatening complications of COVID-19 infections. Sanofi is also working with local governments and health authorities that have officially requested the anti-malarial drug for use in COVID-19.
Apart from coordinating with the Coalition for Epidemic Preparedness Innovations (CEPI) to share its vaccine R&D experience, Sanofi is in weekly contact with the European Commission and EMA to help monitor the impact of COVID-19 on medicines and vaccines supply in Europe.Sanofi’s recently announced its intention to create a leading active pharmaceutical ingredients (API) company based in France by combining six of its European sites. While it is unrelated to COVID-19, it is relevant to the current situation. API are the essential molecules responsible for the beneficial effects used in the composition of any drug. Sanofi’s aim is to secure significant API manufacturing and supply capacities that are critical for patients in Europe, and beyond. Strong political support for this type of initiative is needed.
Servier actively contributes to the fight against the pandemic on the ground, through several initiatives such as providing personal protection equipment to hospitals in several affected countries, as well as making donations to foundations and NGOs (e.g.: Chinese Red Cross and APHP Foundation). In France, Servier’s home country, the company also brings its expertise to the multi-stakeholders partnership “Health Innovation Coalition – Health Crisis″ that aims to develop innovative solutions to relieve congestion in the healthcare system and ensure patients with chronic diseases continue to be treated. In addition, tens of healthcare professionals employed by Servier have volunteered and have been made available to French health authorities to join medical staff on the front line against the virus. Servier puts its best efforts to ensure the continuity of its production in order for its medicines to remain available to patients relying on them
These are challenging times. The surge of cases of COVID-19 is having a profound impact on people around the world, putting pressure on our health systems and disrupting all our daily lives.
It is heartening to seeing the wave of solidarity coming from companies, organizations and individuals. At UCB we are also looking to do our part.
Our action is based on three pillars:
· Contributing to basic research and treatment development
· Offering our expertise to increase local testing capabilities
· Supporting locally and globally through donations as well as direct assistance to patients and partners.
Coronavirus – your questions answered
What is the industry in Europe doing to help in the fight against the coronavirus? What are the risks of drug shortage caused by the coronavirus?Read more
European research-based industry publishes commitments on tackling COVID-19With Europe at the epicentre of the COVID-19 crisis, the researched-based pharmaceutical industry is coming together to commit its resources, expertise and people to the fight against COVID-19.01.04.20Read Article
Pharma volunteering during Covid-19 crisis (Guest blog)A blog from Innovative Pharmaceutical Initiative – iF!, the Croatian association of innovative pharmaceutical manufacturers30.03.20Read Article
Patient Organisations and Europe’s fight against COVID-19: Industry – let’s step upIn the midst of this unprecedented situation patients communities represent, and care for, those most vulnerable to the impact of COVID-19.30.03.20Read Article
Europe’s fight against COVID-19: EFPIA welcomes last night’s Statement of the Members of the European CouncilWe stand shoulder to shoulder with Heads of States and European governments in their efforts to limit the spread of the virus, provide medical equipment, promote research and tackle the socio-economic consequences of the COVID-19 crisis.27.03.20Read Article
#COVID19 and cancer (Guest blog)An open letter from Bettina Ryll to all cancer patient advocates26.03.20Read Article
COVID-19 – Fighting the fakesIn times of crisis like the current COVID-19 pandemic, unfortunately, there is always someone looking to make a quick buck.25.03.20Read Article
Leadership at times of uncertainty (Guest blog)Dealing with the challenges of operating in a VUCA environment24.03.20Read Article
Pharma boss: EU will have to focus on long-term medical research ecosystemIn an interview with Euractiv, Nathalie Moll said that EFPIA members are working around the clock to find vaccines, diagnostics and treatments to use in the fight against coronavirus.23.03.20Read Article
Europe’s COVID-19 battle: Update on the supply of medicines to the patients that need themAt this point EFPIA members do not anticipate impacts to their supply chains unless disruption due to the COVID-19 outbreak is sustained over several months.23.03.20Read Article
Europe’s COVID-19 battle: working together to ensure the supply of medicines to the patients that need themEFPIA warmly welcomes this week’s adoption of a range of measures aimed at maintaining the free circulation of medicines around Europe.18.03.20Read Article
Europe’s COVID-19 battle: supply, support and the search for diagnostics, vaccines, treatments and curesIn any health emergency from HIV to SARS, Ebola to the coronavirus, attention turns to the research-based biopharmaceutical industry to discover and develop vaccines, diagnostics, treatments and cures.18.03.20Read Article
Tackling COVID-19: EFPIA welcomes proactive and regular dialogue with Commissioners on the supply of medicines during the COVID-19 pandemicEFPIA joined a call with Health Commissioner Kyriakides, Commissioner Breton and Commissioner Lenarčič to discuss the potential impact of the coronavirus on the supply of vaccines and medicines.13.03.20Read Article
EFPIA update on research-based pharmaceutical industry response to COVID-19The advent of a global health emergency such as coronavirus underlines the need for a collaborative, dynamic, responsive and empowered research eco-system in Europe.11.03.20Read Article
IMI opens registrations for a webinar on the Coronavirus CallThe Innovative Medicines Initiative to launch EUR 45 million Call for proposals on COVID-19 early March20.02.20Read Article
Joining the fight against coronavirusWe have issued a call to EFPIA members to identify suitable assets in their libraries that could be utilized in the fight against coronaviruses.04.02.20Read Article
- Read IMI2 – Call 21 details
- Watch the video on IMI coronavirus Call
- Factsheet on IMI coronavirus Call
Related websitesWHO website
European Centre for Disease Prevention and Control
The coronavirus response by the European Commission
EU research projects on coronaviruses
GloPID-R, a unique international network of major research funding organisations